Altogether, plasma P-tau181, GFAP and NfL seem to be feasible biomarkers to detect different Alzheimer's disease-related pathologies already in presymptomatic individuals. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.